Physician profile
John A Roper
NPI 1750389334
$1,544.58
in general payments reported to CMS, 2019-2025
14 companies · $444 in 2025
The $444 reported for 2025 was more than what 89% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $55.97 · 2022: $109 · 2023: $359 · 2024: $447 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909 · Education: $190 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.23 |
| Education | $189.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $517.67 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $327.15 | 2019-2025 | |
| Inspire Medical Systems, INC. | $186.59 | 2023-2024 | Inspire |
| Fisher & Paykel Healthcare INC | $185.50 | 2022-2025 | Fisher & Paykel Healthcare |
| Glaxosmithkline, LLC. | $58.43 | 2019-2023 | Trelegy Ellipta |
| Gilead Sciences, INC. | $44.28 | 2021 | |
| Amgen INC. | $41.85 | 2019 | |
| Resmed Corp | $36.34 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $34.86 | 2025 | Lumryz |
| Vanda Pharmaceuticals INC. | $34.64 | 2022 | |
| Zoll Respicardia, INC. | $29.58 | 2025 | Remede System |
| Mallinckrodt Enterprises LLC | $22.77 | 2019 | |
| Allergan, INC. | $13.36 | 2019 | |
| Itamar Medical INC | $11.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.